Is there a role for use of dupilumab for hypereosinophilic GI disorders distal to the esophagus?  

No definitive studies performed yet and no FDA approval regarding using Dupilumab for EoG; however, in my opinion, I do believe that Dupilumab may be an effective treatment for some eosinophilic disorders beyond the esophagus.

I presume that the question is referring to eosinophilic gastrointestinal diseases (EGID) below the esophagus rather than hypereosinophilic syndrome (HES) with GI involvement. The latter would be more concerning for the usage of dupilumab. For non-EoE EGID, evidence is lacking for the clinical benef...